Cyrus Biotechnology Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 35

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $18.4M

  • Investors
  • 20

Cyrus Biotechnology General Information

Description

Operator of a biotech company designed to combine protein design and screening to create novel biologics for serious unmet medical needs. The company's software provides a portal for protein structure prediction, modeling, stabilization, engineering, and design to accelerate the discovery of biology and small molecules, enabling users to get assistance in molecular, homology, and protein modeling.

Contact Information

Website
www.cyrusbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Enterprise Systems (Healthcare)
Primary Office
  • 3005 1st Avenue
  • Suite 203
  • Seattle, WA 98121
  • United States
+1 (206) 000-0000

Cyrus Biotechnology Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cyrus Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 05-Oct-2021 $18.4M 000.00 000.00 Completed Generating Revenue
5. Debt - PPP 15-Apr-2020 00000 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 27-Jul-2017 00.000 000.00 0000 Completed Generating Revenue
3. Seed Round 17-Feb-2017 00.000 00.000 00.000 Completed Generating Revenue
2. Grant 01-Jan-2016 $225K Completed Generating Revenue
1. Grant 12-Dec-2014 $50K Completed Startup
To view Cyrus Biotechnology’s complete valuation and funding history, request access »

Cyrus Biotechnology Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed 5,637,827 $0.000100 8% $0.7 $0.7 1x $0.7 10.65%
To view Cyrus Biotechnology’s complete cap table history, request access »

Cyrus Biotechnology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotech company designed to combine protein design and screening to create novel biologics for serious unm
Other Healthcare Technology Systems
Seattle, WA
35 As of 2023
000.00
00.00 0000-00-00
00000000000 000.00

000000

et, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et d
0000000000000
Vilnius, Lithuania
00 As of 0000
00000
0000000000 0 00000

000000

nt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000000 0000000000 (
Montreal, Canada
00 As of 0000
00000000. 00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cyrus Biotechnology Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biomatter Venture Capital-Backed Vilnius, Lithuania 00 00000 0000000000 0 00000
00000000 000000000 Private Equity-Backed Montreal, Canada 00 00000000. 00
000000 (000000000 Venture Capital-Backed San Diego, CA 00 00000 00000000000 00000
000000 00000000 00 Corporation Simsbury, CT 00 0000000000
0000000 Formerly VC-backed Toronto, Canada 00 000.00 000000&0 000.00
You’re viewing 5 of 9 competitors. Get the full list »

Cyrus Biotechnology Executive Team (5)

Name Title Board Seat Contact Info
Lucas Nivon Ph.D Co-Founder, Chief Executive Officer & Board Member
Yifan Song Ph.D Co-Founder, Chief Science Officer & Board Member
David Baker Scientific Co-Founder & Advisor
You’re viewing 3 of 5 executive team members. Get the full list »

Cyrus Biotechnology Board Members (10)

Name Representing Role Since
Augustus Tai Trinity Ventures Board Member 000 0000
Carl Gordon Ph.D OrbiMed Board Observer 000 0000
Chad Waite Jr. The W Fund Board Member 000 0000
Eric Bell SpringRock Ventures Board Observer 000 0000
Eric Larsen Self Board Observer & Advisor 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Cyrus Biotechnology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cyrus Biotechnology Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Agent Capital Venture Capital Minority 000 0000 000000 0
Alumni Ventures Venture Capital Minority 000 0000 000000 0
Argonautic Ventures Venture Capital Minority 000 0000 000000 0
iSelect Fund Venture Capital Minority 000 0000 000000 0
Selecta Biosciences Corporation Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »

Ready to get started?

Request a free trial